France· FR:61177887
BREVIBLOC 10 mg/ml, solution pour perfusion
A esmolol product containing chlorhydrate d'esmolol, registered in France by BAXTER. The same ATC class is registered in 16 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Esmolol is registered in 16 of 19 countries.
Countries holding a registration under ATC C07AB09 (esmolol), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 9 of them publish a price we can compare per daily dose
Esmolol · ATC C07AB09
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CHLORHYDRATE D'ESMOLOL
- Manufacturer
- BAXTER
- Country
- France (FR)
- ATC code
- C07AB09
- ATC class
- Esmolol
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009563544741 poche(s) en plastique polyoléfine de 250 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
196 interactions on record for esmolol.
Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Esmolol · interactions on record
196 records
- 11 severe
- 139 moderate
- 8 minor
Most severe, free to view
- DolasetronA04AA04severe
- TheophyllinC01EB28severe
- CeritinibL01ED02severe
- CeritinibL01XE28severe
38 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Esmolol in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsBrevibloc 10 mg/ml, oplossing voor infusieBaxter B.V.
- United StatesBreviblocHenry Schein, Inc
- United KingdomBrevibloc Concentrate 2.5g/10ml solution for infusion ampoulesBaxter Healthcare Ltd
- FinlandBreviblocBaxter Oy
- GermanyBreviblocBaxter Deutschland Gmbh
- SwitzerlandBrevibloc 100 mg, InjektionslösungBaxter AG
- SpainBREVIBLOC 10 mg/ml SOLUCION INYECTABLEBaxter S.L.
- BelgiumBrevibloc 10 mg/mlBaxter
Authorised across Europe · EMA
The same active substance is authorised in 21 EEA countries. Names it is sold under:
- Austria · Brevibloc, Esmolol Amomed
- Belgium · Brevibloc
- Cyprus · Brevibloc, Esmobeta
- Czechia · Esmocard, Esmocard Lyo
- Germany · Brevibloc, Esmocard
- Denmark · Brevibloc
- Spain · Brevibloc, Esmolol Aurovitas
- Finland · Brevibloc
- United Kingdom (Northern Ireland) · Brevibloc Premixed, Esmolol Hikma Farmacêutica (Portugal)
- Greece · Brevibloc, Esmobeta
- Croatia · Esmocard
- Ireland · Brevibloc Premixed
- Italy · Brevibloc, Esmocard
- Luxembourg · Brevibloc
- Malta · Brevibloc Premixed
- Netherlands · Brevibloc, Esmolol Hcl Hikma
- Norway · Brevibloc
- Portugal · Brevibloc, Esmolol Eugia
- Sweden · Brevibloc
- Slovenia · Esmocard, Esmocard Lyo
- Slovakia · Esmocard, Esmocard Lyo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/760ae5bd-fe1f-4f04-bf94-c964931f5cd2 GET /v1/drugs/760ae5bd-fe1f-4f04-bf94-c964931f5cd2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "61177887",
"date_amm": "2001-09-13",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "CHLORHYDRATE D'ESMOLOL",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about esmolol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.